April 4 (Reuters) - Johnson & Johnson JNJ.N:
TREMFYA® (GUSELKUMAB) IS THE FIRST AND ONLY IL-23 INHIBITOR TO SIGNIFICANTLY REDUCE BOTH THE SIGNS AND SYMPTOMS AND THE PROGRESSION OF STRUCTURAL DAMAGE IN ADULTS LIVING WITH ACTIVE PSORIATIC ARTHRITIS
JOHNSON & JOHNSON - TREMFYA PHASE 3B STUDY ACHIEVES PRIMARY AND SECONDARY ENDPOINTS
JOHNSON & JOHNSON - TREMFYA SAFETY PROFILE CONSISTENT WITH NO NEW SAFETY SIGNALS
JOHNSON & JOHNSON - TREMFYA SHOWS LESS STRUCTURAL DAMAGE PROGRESSION AT WEEK 24
Source text: ID:nPn70mvxba
Further company coverage: JNJ.N
(((( Reuters.briefs@thomsonreuters.com ;));))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。